X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (11593) 11593
Book Chapter (9) 9
Magazine Article (5) 5
Publication (4) 4
Book / eBook (2) 2
Dissertation (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7795) 7795
quinazolines - pharmacology (7745) 7745
animals (5227) 5227
male (3214) 3214
female (3174) 3174
oncology (3056) 3056
cell line, tumor (2573) 2573
mice (2530) 2530
antineoplastic agents - pharmacology (2328) 2328
pharmacology & pharmacy (2267) 2267
quinazolines - therapeutic use (2165) 2165
receptor, epidermal growth factor - antagonists & inhibitors (1843) 1843
protein kinase inhibitors - pharmacology (1611) 1611
rats (1585) 1585
gefitinib (1511) 1511
chemistry, medicinal (1478) 1478
cancer (1476) 1476
quinazolines - chemistry (1459) 1459
receptor, epidermal growth factor - metabolism (1360) 1360
middle aged (1356) 1356
quinazolines - administration & dosage (1332) 1332
quinazolines - chemical synthesis (1324) 1324
cell proliferation - drug effects (1252) 1252
dose-response relationship, drug (1251) 1251
expression (1250) 1250
lung neoplasms - drug therapy (1237) 1237
adult (1158) 1158
erlotinib hydrochloride (1118) 1118
structure-activity relationship (1108) 1108
aged (1096) 1096
biochemistry & molecular biology (1029) 1029
antineoplastic agents - therapeutic use (1016) 1016
phosphorylation (993) 993
enzyme inhibitors - pharmacology (991) 991
growth-factor receptor (979) 979
carcinoma, non-small-cell lung - drug therapy (974) 974
apoptosis - drug effects (971) 971
apoptosis (968) 968
egfr (961) 961
signal transduction - drug effects (949) 949
receptor, epidermal growth factor - genetics (933) 933
quinazolines (890) 890
mutation (887) 887
epidermal growth factor (835) 835
chemotherapy (809) 809
tyrosine kinase inhibitor (784) 784
erlotinib (783) 783
activation (769) 769
analysis (765) 765
quinazolines - adverse effects (765) 765
signal transduction (757) 757
cell biology (752) 752
lung neoplasms - pathology (708) 708
research (681) 681
quinazolines - pharmacokinetics (679) 679
tyrphostins - pharmacology (675) 675
mice, nude (654) 654
xenograft model antitumor assays (651) 651
molecular structure (646) 646
drug resistance, neoplasm (625) 625
lung neoplasms - genetics (613) 613
cell survival - drug effects (594) 594
treatment outcome (584) 584
tumor cells, cultured (584) 584
protein kinase inhibitors - therapeutic use (571) 571
cell line (567) 567
lung cancer (549) 549
cell lung-cancer (547) 547
drug synergism (543) 543
kinases (542) 542
phosphorylation - drug effects (540) 540
resistance (540) 540
tyrosine (536) 536
therapy (534) 534
time factors (534) 534
cells, cultured (532) 532
blotting, western (526) 526
antineoplastic combined chemotherapy protocols - therapeutic use (522) 522
breast neoplasms - drug therapy (516) 516
care and treatment (507) 507
in-vitro (506) 506
carcinoma, non-small-cell lung - pathology (504) 504
tumors (504) 504
cells (500) 500
in vitro techniques (495) 495
breast cancer (489) 489
mutations (489) 489
growth (479) 479
inhibition (475) 475
quinazolines - metabolism (465) 465
antineoplastic agents - chemistry (461) 461
proteins (461) 461
chemistry, organic (460) 460
inhibitors (456) 456
carcinoma, non-small-cell lung - genetics (452) 452
epidermal growth factor receptor (445) 445
lung-cancer (445) 445
neoplasms - drug therapy (443) 443
quinazoline (442) 442
receptor, erbb-2 - metabolism (442) 442
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (11237) 11237
Japanese (249) 249
Chinese (154) 154
German (149) 149
French (38) 38
Italian (23) 23
Spanish (23) 23
Russian (22) 22
Hungarian (15) 15
Ukrainian (15) 15
Polish (11) 11
Czech (4) 4
Portuguese (3) 3
Bulgarian (2) 2
Danish (2) 2
Norwegian (2) 2
Croatian (1) 1
Hebrew (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of inorganic biochemistry, ISSN 0162-0134, 12/2015, Volume 153, pp. 49 - 59
Heart tissue becomes zinc-depleted and the capacity to mobilize labile zinc is diminished, indicating zinc dyshomeostasis during ischemia/reperfusion (I/R).... 
Hypoxia | Reoxygenation | Proteolysis | Caspase-3 | Zinc | Apoptosis | ACTIVATION | RAT | MITOCHONDRIAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | REPERFUSION INJURY | CARDIOMYOPATHY | CARDIAC-CELLS | DEATH | INTRACELLULAR ZINC | CHEMISTRY, INORGANIC & NUCLEAR | ACUTE MYOCARDIAL-INFARCTION | Receptor, Epidermal Growth Factor - genetics | Caspase Inhibitors - pharmacology | Phosphorylation | Receptor, ErbB-2 - genetics | Protein Multimerization | Caspase 3 - metabolism | Receptor, ErbB-2 - metabolism | RNA, Messenger - metabolism | Cell Hypoxia | Receptor, Epidermal Growth Factor - metabolism | Zinc Compounds - pharmacology | Amino Acid Chloromethyl Ketones - pharmacology | Receptor, ErbB-2 - antagonists & inhibitors | Proteasome Inhibitors - pharmacology | Benzothiazoles - pharmacology | Chlorides - pharmacology | Down-Regulation | RNA, Messenger - genetics | Rats | Tyrphostins - pharmacology | Cardiotonic Agents - pharmacology | Leupeptins - pharmacology | Myocytes, Cardiac - pathology | Animals | Myocytes, Cardiac - drug effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Thiones - pharmacology | Quinazolines - pharmacology | Organometallic Compounds - pharmacology | Proteins | Membrane lipids | Inositol | RNA | Antifungal agents | Permeability | Antibacterial agents | Phosphotransferases | Tyrosine | Cell death
Journal Article
Journal Article
Clinical cancer research, ISSN 1557-3265, 2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | RESISTANCE | EGFR MUTATIONS | KINASE INHIBITORS | ANTITUMOR-ACTIVITY | CHEMOTHERAPY | ZD1839 | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology
Journal Article
Clinical cancer research, ISSN 1078-0432, 08/2016, Volume 22, Issue 15, pp. 3884 - 93
PURPOSE: FGFR1 is a promising therapeutic target in multiple types of solid tumors, including head and neck squamous cell carcinoma (HNSCC). FGFR inhibitors... 
Head and Neck Neoplasms/diagnosis | Prognosis | Humans | Middle Aged | Male | Quinazolines/pharmacology | Molecular Targeted Therapy | Biomarkers, Tumor | Antineoplastic Agents/pharmacology | Neoplasm Metastasis | Squamous Cell Carcinoma of Head and Neck | Aged, 80 and over | Adult | Female | Carcinoma, Squamous Cell/diagnosis | Gefitinib | Gene Expression | Piperazines/pharmacology | Receptor, Fibroblast Growth Factor, Type 1/antagonists & inhibitors | Kaplan-Meier Estimate | Benzamides/pharmacology | Combined Modality Therapy | Gene Amplification | Pyrazoles/pharmacology | Cell Line, Tumor | Aged | Neoplasm Staging | AMPLIFICATIONS | SURVIVAL | DEFINITION | MECHANISM | ONCOLOGY | PROTEIN EXPRESSION | TUMOR | FIBROBLAST-GROWTH-FACTOR | LESSONS | FACTOR RECEPTOR | CANCER | Pyrazoles - therapeutic use | Carcinoma, Squamous Cell - metabolism | Receptor, Fibroblast Growth Factor, Type 1 - metabolism | Antineoplastic Agents - therapeutic use | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Head and Neck Neoplasms - metabolism | Carcinoma, Squamous Cell - diagnosis | Benzamides - therapeutic use | Carcinoma, Squamous Cell - mortality | Antineoplastic Agents - pharmacology | Benzamides - pharmacology | Pyrazoles - pharmacology | Head and Neck Neoplasms - drug therapy | Piperazines - therapeutic use | Piperazines - pharmacology | Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors | Carcinoma, Squamous Cell - drug therapy | Quinazolines - therapeutic use | Head and Neck Neoplasms - diagnosis | Head and Neck Neoplasms - mortality | Quinazolines - pharmacology
Journal Article
Arteriosclerosis, thrombosis, and vascular biology, ISSN 1079-5642, 09/2014, Volume 34, Issue 9, pp. 2078 - 2085
OBJECTIVE—In a phase III clinical trial (PLATelet inhibition and patient Outcomes, PLATO), ticagrelor provided better clinical outcomes than clopidogrel in... 
adenosine | aspirin | cyclooxygenase | platelet aggregation inhibitors | ISCHEMIA/REPERFUSION INJURY | ACUTE CORONARY SYNDROMES | PLATO | COMBINATION | ATORVASTATIN | ISCHEMIA-REPERFUSION INJURY | CLOPIDOGREL | PLATELET INHIBITION | PERIPHERAL VASCULAR DISEASE | CARDIOPROTECTION | HEMATOLOGY | Receptor, Adenosine A1 - physiology | Ticlopidine - therapeutic use | Nitric Oxide Synthase Type III - biosynthesis | Adenosine A1 Receptor Antagonists - pharmacology | Male | Receptor, Adenosine A2A - physiology | Cardiotonic Agents - therapeutic use | Cyclooxygenase 2 - biosynthesis | Myocardial Reperfusion Injury - pathology | Cyclooxygenase 2 - genetics | Adenosine - therapeutic use | Myocardial Infarction - pathology | Enzyme Induction - drug effects | Nitric Oxide Synthase Type III - physiology | Aspirin - pharmacology | Myocardial Reperfusion Injury - drug therapy | Drug Evaluation, Preclinical | Pyrazoles - pharmacology | Cyclooxygenase 2 Inhibitors - pharmacology | Rats | Cyclooxygenase 2 - physiology | Adenosine - pharmacology | Cardiotonic Agents - pharmacology | Nitric Oxide Synthase Type III - genetics | Rats, Sprague-Dawley | Ticlopidine - analogs & derivatives | Triazoles - pharmacology | Up-Regulation - drug effects | Adenosine A2 Receptor Antagonists - pharmacology | Animals | Myocardial Infarction - drug therapy | Adenosine - analogs & derivatives | Adenosine - physiology | 6-Ketoprostaglandin F1 alpha - metabolism | Quinazolines - pharmacology | Lipoxins - metabolism | Myocardial Reperfusion Injury - prevention & control
Journal Article
British journal of pharmacology, ISSN 0007-1188, 12/2014, Volume 171, Issue 24, pp. 5757 - 5773
Journal Article
The Journal of Clinical Endocrinology & Metabolism, ISSN 0021-972X, 07/2013, Volume 98, Issue 7, pp. E1163 - E1172
Context: Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase glucose-dependent insulinotropic polypeptide and glucagon like peptide 1... 
APOPTOSIS | HUMAN PANCREATIC-ISLETS | METABOLIC SYNDROME | HYPERGLYCEMIA | ALPHA-CELLS | GLUCOSE | ENDOCRINOLOGY & METABOLISM | RECEPTOR EXPRESSION | RANDOMIZED CONTROLLED-TRIAL | BI 1356 | DIPEPTIDYL PEPTIDASE-IV | Palmitic Acid - metabolism | Dipeptidyl Peptidase 4 - metabolism | Antioxidants - chemistry | Dipeptidyl Peptidase 4 - chemistry | Humans | Interleukin 1 Receptor Antagonist Protein - genetics | Peptide Fragments - pharmacology | Interleukin-1beta - genetics | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Anti-Inflammatory Agents, Non-Steroidal - pharmacology | Insulin-Secreting Cells - metabolism | Anti-Inflammatory Agents, Non-Steroidal - antagonists & inhibitors | Glucagon-Like Peptide 1 - agonists | Interleukin-1beta - metabolism | Interleukin 1 Receptor Antagonist Protein - metabolism | Purines - antagonists & inhibitors | Linagliptin | Interleukin 1 Receptor Antagonist Protein - pharmacology | Sitagliptin Phosphate | Insulin Secretion | Interleukin-1beta - antagonists & inhibitors | Recombinant Proteins - metabolism | Cell Survival - drug effects | Recombinant Proteins - antagonists & inhibitors | Cytokines - metabolism | Glucagon-Like Peptide 1 - metabolism | Purines - pharmacology | Tissue Culture Techniques | Dipeptidyl-Peptidase IV Inhibitors - chemistry | Glucagon-Like Peptide 1 - chemistry | Antioxidants - pharmacology | Recombinant Proteins - pharmacology | Insulin-Secreting Cells - immunology | Triazoles - pharmacology | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Drug Inverse Agonism | Protein Stability - drug effects | Pyrazines - pharmacology | Quinazolines - pharmacology | Quinazolines - antagonists & inhibitors
Journal Article
The Journal of biological chemistry, ISSN 0021-9258, 08/2013, Volume 288, Issue 32, pp. 22942 - 22960
TGR5 is a G protein-coupled receptor that mediates bile acid (BA) effects on energy balance, inflammation, digestion, and sensation. The mechanisms and... 
GROWTH-FACTOR RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | GPBAR1 TGR5 | DEPENDENT ENDOCYTOSIS | PROTEIN-COUPLED RECEPTORS | RESONANCE ENERGY-TRANSFER | KINASE ACTIVATION | MU-OPIOID RECEPTOR | BETA-ADRENERGIC RECEPTOR | ACTIVATED RECEPTOR-2 | EGF RECEPTOR | Cholagogues and Choleretics - pharmacology | Phenylalanine - analogs & derivatives | Receptors, G-Protein-Coupled - metabolism | Membrane Microdomains - metabolism | Phenylalanine - pharmacology | Humans | ErbB Receptors - genetics | Oleanolic Acid - pharmacology | Arrestins - genetics | Protein Transport - physiology | Protein Transport - drug effects | G-Protein-Coupled Receptor Kinase 2 - genetics | G-Protein-Coupled Receptor Kinase 2 - metabolism | Arrestins - metabolism | beta-Cyclodextrins - pharmacology | Endosomes - metabolism | Mitogen-Activated Protein Kinase 1 - genetics | HEK293 Cells | Antineoplastic Agents - pharmacology | Cyclic AMP - genetics | Cyclic AMP - metabolism | ErbB Receptors - antagonists & inhibitors | ErbB Receptors - metabolism | Endosomes - genetics | Mitogen-Activated Protein Kinase 3 - genetics | Endocytosis - drug effects | Enzyme Inhibitors - pharmacology | Thiophenes - pharmacology | Tyrphostins - pharmacology | Endocytosis - physiology | Arrestins - antagonists & inhibitors | G-Protein-Coupled Receptor Kinase 5 - metabolism | Deoxycholic Acid - pharmacology | Mitogen-Activated Protein Kinase 3 - metabolism | beta-Arrestin 2 | beta-Arrestin 1 | beta-Arrestins | Receptors, G-Protein-Coupled - genetics | Quinazolines - pharmacology | G-Protein-Coupled Receptor Kinase 5 - genetics | Membrane Microdomains - genetics | Mitogen-Activated Protein Kinase 1 - metabolism | Lipid Raft | Bile Acid | Endocytosis | G Protein-coupled Receptors (GPCR) | Arrestin | Signal Transduction
Journal Article
Nature cell biology, ISSN 1476-4679, 2011, Volume 13, Issue 10, pp. 1265 - 1271
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 04/2004, Volume 109, Issue 14, pp. 1795 - 1801
Background - Isoforms of the NADPH oxidase contribute to vascular superoxide anion (.O-2(-)) formation and limit NO bioavailability. We hypothesized that the... 
Hypertension | Stress, oxidative | Angiotensin | Endothelium | endothelium | CELLS | PROTEIN-KINASE-C | CARDIAC & CARDIOVASCULAR SYSTEMS | stress, oxidative | SUPEROXIDE-PRODUCTION | INVOLVEMENT | ANGIOTENSIN-II | SYNTHASE | PRESSURE | NAD(P)H OXIDASE | angiotensin | TETRAHYDROBIOPTERIN | PERIPHERAL VASCULAR DISEASE | hypertension | EXPRESSION | Angiotensin II - blood | Male | 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt - pharmacology | Hypertension, Renovascular - physiopathology | Quinazolines | Endothelium, Vascular - enzymology | Glycoproteins - pharmacology | Cytochromes b - deficiency | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Superoxides - metabolism | Aorta | Indoles - pharmacology | Membrane Glycoproteins | Cardiomyopathy, Hypertrophic - etiology | Organ Culture Techniques | Disease Models, Animal | Polyethylene Glycols - pharmacology | NADPH Oxidases | Superoxide Dismutase - pharmacology | Vasodilator Agents - pharmacology | Acetylcholine - pharmacology | Hypertension, Renovascular - enzymology | Mice, Inbred C57BL | Endothelium, Vascular - physiopathology | Enzyme Inhibitors - pharmacology | Protein Kinase C - antagonists & inhibitors | Tyrphostins - pharmacology | Antioxidants - pharmacology | NADPH Oxidase 2 | Mice, Knockout | Proto-Oncogene Proteins c-akt | Animals | Hypertension, Renovascular - complications | Bacterial Toxins - pharmacology | Cytochromes b - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Vasodilation - drug effects | Nitric Oxide - metabolism | Cytochromes b - physiology
Journal Article
Nature (London), ISSN 1476-4687, 2012, Volume 487, Issue 7408, pp. 505 - 509
Mutationally activated kinases define a clinically validated class of targets for cancer drug therapy(1). However, the efficacy of kinase inhibitors in... 
CELL LUNG-CANCER | SURVIVAL | HETEROGENEITY | ACTIVATION | RECEPTOR TYROSINE KINASES | THERAPY | MET AMPLIFICATION | MULTIDISCIPLINARY SCIENCES | ACQUIRED-RESISTANCE | SENSITIVITY | TUMOR-CELLS | Receptor, ErbB-2 - genetics | Humans | Receptor, ErbB-2 - metabolism | Melanoma - enzymology | Phosphatidylinositol 3-Kinases - metabolism | Hepatocyte Growth Factor - pharmacology | Breast Neoplasms - metabolism | Melanoma - genetics | Female | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Cell Survival - drug effects | Melanoma - pathology | Receptor Protein-Tyrosine Kinases - metabolism | Sulfonamides - pharmacology | Breast Neoplasms - drug therapy | Hepatocyte Growth Factor - metabolism | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Breast Neoplasms - genetics | Signal Transduction - drug effects | Breast Neoplasms - pathology | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Cell Line, Tumor | Ligands | Protein Kinase Inhibitors - pharmacology | Quinazolines - pharmacology | Drug Resistance, Neoplasm - drug effects | Mitogen-Activated Protein Kinases - metabolism | Antimitotic agents | Physiological aspects | Antineoplastic agents | Growth factors | Health aspects | Phosphotransferases | Substance abuse treatment | Epidermal growth factor | Rodents | Biomarkers | Breast cancer | Insulin-like growth factors | Kinases | Drug resistance | Tumors
Journal Article